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Abstract Introduction The platelet function analyzer (PFA) is widely used as a screening tool for
bleeding disorders in various settings. The diagnostic performance regarding platelet
function disorders (PFDs), which are among the most common inherited bleeding
disorders, is however still elusive. We aimed to assess the diagnostic value of PFA for
PFD in clinical practice.
Methods Comprehensive clinical and laboratory data of all consecutive patients
referred to a specialized outpatient between January 2012 and March 2017 with a
suspected bleeding disorder were prospectively recorded. The diagnostic work-up was
performed according to a prespecified protocol following current guidelines and
platelet function was tested using light transmission aggregometry as well as flow
cytometry.
Results Five hundred and fifty-five patients were included (median age 43.7 years;
interquartile range [IQR] 29.3, 61.7; 66.9% female). Possible PFD was diagnosed in 64
patients (11.5%) and confirmed PFD in 54 patients (9.7%). In patients with confirmed
PFD, median closure times were 107 seconds (ADP or adenosine diphosphate; IQR 89,
130) and 169 seconds (EPI; IQR 121, 211). In patients without bleeding disorders, PFA
closure times were 96 seconds (ADP; IQR 83, 109) and 137 seconds (EPI; IQR 116, 158).
The sensitivity was 19.5% in case of PFA ADP (95%CI 12.6, 30.0; specificity 86.4%; 95% CI
82.4, 89.8), and 44.3% in case of PFA EPI (95% CI 34.9, 53.9; specificity 75.6%; 95% CI
70.8, 79.9).
Conclusion The diagnostic performance of PFA for PFD was moderate to poor. Our
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Hereditary platelet function disorders (PFDs) are among the
most common causes of a bleeding disorder that manifest in
the context of trauma and/or medical interventions.1,2How-
ever, diagnosing PFD is difficult and many patients probably
remain unidentified, exposing them to a risk for bleeding in
the periinterventional setting.3 Severe disorders such as
Glanzmann thrombasthenia (GT), Bernard-Soulier syndrome
(BSS), or syndromic disorders manifest with a moderate to
severe bleeding phenotype and are rather straightforward to
diagnose.4 In contrast, the majority of PFDs are much more
difficult to recognize and diagnose. Bleeding symptoms are
often mild and patients can be barely distinguished from
healthy individuals. Appropriate laboratory tests are avail-
able only in specialized laboratories because PFD tests are
technically challenging, time-consuming, and difficult to
interpret.3,5 Because of complex preanalytic requirements,
blood drawing has to be done on site at the laboratory rather
than having the sample shipped from farther afield.6,7 A
screening test would be of great value in the work-up of
patients with suspected PFD.
Due to its simplicity of use and a high sensitivity with
regard to several factors affecting primary hemostasis, the
PFA has been implementedwidely in thework-up of patients
with a suspected bleeding disorder.8,9 Some authors have
considered the so-called “in vitro bleeding time” to be at
least as sensitive as the light transmission aggregometry
approach and even more sensitive than the skin bleeding
time (IVY method).8–10 In addition, PFA has been suggested
as a preoperative screening tool11,12 and several studies have
confirmed a very high sensitivity with regard to von Wille-
brand disease.13 In addition, PFA is an excellent means to
monitor the treatment with desmopressin in patients with
vonWillebrand disease.14Moreover, PFA is very sensitive for
the presence of aspirin.15 Data are much more heterogenous
with regard to PFD.8 PFA appears to detect all patients with a
severe PFD such as GT or BSS.8,10,13 Only a few studies have
investigated the diagnostic accuracy with regard tomild PFD
and the results vary considerably.8 A large prospective study
conducted in a representative, unselected cohort of patients
with a broad range of PFD is however still missing. Thus,
whether or not PFA can be used as a screening tool for PFD
remains unclear.
With the present study, we aimed to assess the diagnostic
value of the PFA for a variety of PFD in a large representative
cohort of patients.
Methods
Study Design, Setting, and Population
All consecutive patients aged 18 years or older, referred
between January 2012 and March 2017 to our specialized
outpatient unit of Inselspital University Hospital with a
suspected bleeding disorder were included and data were
prospectively recorded. The study population is regarded as
representative for Switzerland for the following reasons: the
Inselspital is a tertiary university hospital covering a region
with 1.5million inhabitants; the greater Bern area comprises
rural as well as urban communities; and the canton of Bern
has both French-speaking and German-speaking regions.
The outpatient unit of Inselspital is a reference center for
coagulation disorders and contains the only laboratory with-
in the described area providing a comprehensive set of
laboratory assays. The vast majority of patients with a
suspected bleeding disorder will therefore be referred to
our institution. Reasons for referral included (1) a bleeding
tendency, (c) a family history of bleeding disorders, or (d)
abnormal laboratory test results. The methodology has been
previously described.16
The clinical data were prospectively collected using an
established in-house questionnaire as well as the ISTH-BAT
sheet and stored securely in the electronic hospital database.
Laboratory resultswere savedaccordingly. The patient records
were coded using an in-house identification system and data
were retrievedby two investigators inparallel (M.A./J.K.,M.N.).
All patients signed informed consent and the Ethics Commit-
tee approved the study protocol (No. 02289).
Work-up of Patients
Following previous recommendations, a standardized proto-
col was created and followed in the diagnostic work-up of
patients.5,17–20 First, patients completed a survey focused on
bleeding history and antithrombotic drugs, whichwas provid-
ed by mail in advance of the consultation.21 Second, compre-
hensive bleeding history was taken by trained resident
physicians using a standardized 13-item, in-house question-
naire assessing the presence and severity of bleeding at
specific organs, including the skin, nose, oral cavity, gastroin-
testinal, urogenital, joints andmuscles, bleeding in association
with minor injuries, dental procedures, surgery, transfusion
requirements, bleeding after ingestion of drugs known to
affect hemostasis and family history,21 and the ISTH-BAT
form was completed.17,22 A physical examination was per-
formed, focusing on hematomas or petechia, signs of amyloid-
osis, telangiectasia, as well as hyperflexibility of joints.
Instructions were given to stop antithrombotic treatment,
selective serotonin reuptake inhibitors, and nonsteroidal
anti-inflammatory drugs 10 days prior to investigation.
Patients were additionally instructed to refrain from smoking
and drinking caffeine on the day of consultation.
Handling of Samples
Blood drawing and preparation of blood samples was done
followinga standardizedprotocol inorder toavoidpreanalytical
errors.23 Blood samples were collected by standard venepunc-
turewith a 21-gauge needle. EDTA (ethylenediaminetetraacetic
acid) tubes (Monovette; Sarstedt, Nümbrecht, Germany) were
used for determination of full blood count, citrated tubes
(0.106mol/L trisodium citrate 9:1, v/v) for the determination
of coagulation tests and flow cytometry, as well as buffered
citrate (0.13mol/L trisodium citrate, pH 5.5 corresponding to
3.2% trisodium citrate) for platelet aggregometry as well as
PFA. Samples were transported manually to the laboratory.
Samples were snap-frozen at80°C for some assays conducted
in batches. Platelet rich plasma (PRP) was prepared by
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centrifugation at room temperature for 15minutes at 150 g.
Platelet poor plasma was prepared by centrifugation at 1,500 g
for 15minutes.
Laboratory Work-up
A stepwise approach was used in the laboratory work-up.
The following initial tests were carried out simultaneously:
full blood count and mean platelet volume, a blood smear
analyzing platelet morphology, prothrombin time, activated
partial thromboplastin time, thrombin time (TT), fibrinogen
concentration (Clauss’ method), a2-antiplasmin, a range of
coagulation factors (FII, FV, FVII, FX, FXIII), von Willebrand
factor (VWF) antigen (VWF:Ag), VWF activity (VWF:GPIbM),
and platelet function analyzer (PFA-200). The determina-
tion of light transmission aggregometry (LTA), flow cytom-
etry, and PFA-200 is described in below, all other tests are
characterized in the Supplementary Material. The following
tests were conducted in few selected cases: chromogenic
factor VIII, VWF multimer analysis, VWF-FVIII binding
capacity, lumi-aggregometry, and molecular diagnostics.
Determination of Platelet Function Analyzer
PFA was performed as previously described using a micro-
processor-controlled instrument (PFA-200 and INNOVANCE
PFA-200 System, Siemens Healthcare Diagnostics, Germany)
and a disposable test cartridge.21 For all patients, two
cartridges were used (Dade PFA collagen/epinephrine [des-
ignated here as EPI] and Dade PFA collagen/ADP [designated
here as ADP], Siemens Healthcare Diagnostics, Germany).
The closure times (CTs), defined as the time to full occlusion
of the aperture, were measured for both cartridges. The
established in-house reference ranges were 65 to 130 sec-
onds for ADP and 80 to 170 seconds for EPI.
Determination of Light Transmission Aggregometry
and Platelet Flow Cytometry
We conducted LTA in-line with current recommenda-
tions7,24 and as previously described.21 The aggregometer
APACT 4004V (LABiTec GmbH, Ahrensburg, Germany) was
used. Baseline agonists for platelet aggregation were ADP
(Sigma-Aldrich, St. Louis, Missouri, United States; 4, 6, and
10 μmol/L for male patients and 3, 4, and 6 μmol/L for
female patients), collagen (HORM; Nycomed, Linz, Austria)
at 1.5, 3, and 4 μg/mL, arachidonic acid at 2 mmol/L (Bio
Data/Medonic Servotec AG, Interlaken, Switzerland), and
ristocetin at 1.5 and 0.5 mg/mL (Socochim SA, Lausanne,
Switzerland). Platelet count was adjusted to 250 109/L. In
order to exclude spontaneous aggregation, 200 μL of PRP
prewarmed at 37°C for 1minute, was added to the aggreg-
ometer cuvette and run for an additional minute. After
adding 20 μL of the agonist to the sample, the response
was recorded. In case of a response to one agonist outside
the limits of the normal range, the test was repeated. LTA
was performed between 1 and 2.5 hours after collection of
venous blood samples from the patient. Previously estab-
lished in-house reference values were used for inter-
pretation of the aggregation curves.25 As an internal
control, a sample from a healthy volunteer was analyzed.
LTA was not performed when the platelet count of the
patient was <100 G/L.
Platelet flow cytometry was conducted as previously
described.16,21 The following antihuman antibodies were
used for analysis of surface glycoproteins (GPs): Ibα (mono-
clonal antihumanCD42b-PE; Dako, Baar, Switzerland), GPIIb/
IIIa (anti-hCD41-FITC and anti-hCD61-FITC, Becton Dickin-
son, Allschwil, Switzerland), baseline P-selectin expression
(anti-CD62P-PE, Becton-Dickinson), and PAC-1 binding
(PAC1-FITC, Becton Dickinson). After preparation of the
sample in a 100 μL volume containing platelets at a concen-
tration of 5 106/mL and anti-CD62P-PE and PAC1-FITC,
analysis was performedwith a FACSCanto (BectonDickinson,
Heidelberg, Germany) flowcytometer. By using ADP (0.5, 5.0,
and 50 μmol/L), convulxin (5, 50, and 500 ng/mL), and
thrombin (0.05, 0.5, and 5 μmol/L), the dose response of
platelet reactivity was investigated. The surface expression
of negatively charged phospholipids was investigated using
Annexin V-FITC (Roche, Rotkreuz, Switzerland) after incuba-
tion with either Ionophore A 23187 or the combination of
convulxin (500 ng/mL) and thrombin (5 nmol/L). By loading
platelets withmepacrine (at 0.17 μmol/L as well as 1.7 μmol/
L) and analyzing with thrombin, the content and secretion of
dense granules were evaluated. The in-house reference
values had been previously established.21 A sample from a
healthy volunteer was analyzed in parallel with each run. To
confirm the results, flow cytometric analysis was repeated
once with different control platelets.
Definition of Diagnoses
Bleeding disorders were diagnosed in linewith recent guide-
lines and recommendations; the bleeding history was con-
sidered in addition to laboratory tests. Abnormal laboratory
results were repeated at least once in order to exclude
spurious results.
PFD were categorized into “possible” or “confirmed” PFD
regarding whether or not all platelet function studies were
available. “Confirmed PFDs” were defined as an abnormal
light transmission aggregometry and/or an abnormal plate-
let flow cytometry on two occasions in the absence of other
disorders.5,6 Patients were categorized with a “possible PFD”
if only one measurement was available or there were incon-
clusive results, or concomitant disorders were present. PFDs
were further categorized into eight subgroups: (1) Glanz-
mann’s thrombasthenia, defined as a defect in GPIIb/IIIa
associated with a severely diminished aggregation of all
agonists except ristocetin, reduced expression of GPIIb/IIIa,
and/or markedly reduced activation of PAC1-binding1,3,4,26;
(2) Gi-like defects, defined as an accentuated deficiency in
aggregation to the Gi-coupled receptor antagonists ADP and
adrenaline, associated with corresponding flow cytometry
results,1,3,26 (3) thromboxane A2 pathway defects, defined as
an absent aggregation in response to arachidonic acid, and
possibly associated with an impaired response to other
agonists,1,3,4,24,26 (4) dense granule secretion defects, de-
fined as a defect in storage and/or secretion of mepa-
crine,1,3,4,21,26 (5) collagen receptor defects, defined as an
isolated reduction in aggregation and secretion after
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stimulationwith collagen and convulxin,1,21,26 (6)a-granule
disorders, defined as a reduced expression and/or secretion
of P-selectin, associated with varying impaired aggregation
after stimulation with collagen and epinephrine,1,21 (7)
decreased generation of procoagulant COAT platelets, de-
fined as an impaired binding of Annexin-V after incubation
with convulxin and thrombin,21 (8) complex disorders,
defined as defects in a number of agonists (LTA) and/or
several flow cytometry results that cannot be attributed to
any of the disorders mentioned above. LTA and flow cytom-
etry were interpreted according to previous recommenda-
tions and established in-house reference ranges.21 Three
experienced individuals performed the analyses and dis-
crepancies were resolved by discussion.3,5,6,27–29 Addition-
ally, lumi-aggregometry was considered if available (for a
few patients only).
VWD type 1 was diagnosed with VWF:GPIbM levels of
0.05 to 0.4 U/mL and VWF:Ag of 0.05 to 0.4 U/mL, an VWF:
GPIbM/ VWF:Ag ratio of >0.7, a normal multimer pattern
and a relevant bleeding history (repeated measure-
ments).30–34 Aiming to simplify treatment decisions in clini-
cal practice, we defined a threshold of 0.4 U/mL rather than a
0.3 U/mL.35 VWD type 2 was diagnosed following ISTH
criteria.32 Low VWF was diagnosed in patients with VWF:
GPIbM or VWF:Ag below 0.5 U/mL, not meeting the criteria
mentioned above, and associated with blood group O.19
Hemophilia and other single factor deficiencies were diag-
nosed in accordance with current definitions.36
We categorized a patient with an abnormal ISTH-BAT
(male 4 points; female 6 points) as a “bleeder of
undefined cause” if all other tests mentioned were normal
and no bleeding disorder was identified.37–39 Patients with
a systemic disorder associated with bleeding symptoms
(e.g., hereditary telangiectasia and thrombocytopenia) but
without a hemostatic were categorized as “systemic
disorders.”
Statistical Analysis
The study population was characterized using descriptive
statistics (numbers/percent or median/interquartile range
[IQR] as appropriate). The ability of the PFA to discriminate
between healthy individuals and patients with PFD (sus-
pected or confirmed) was assessed with a receiver-operating
characteristic (ROC) curve analysis. Sensitivity and specifici-
ty were calculated using the in-house reference values and
the reference values of the manufacturer (as a sensitivity
analysis). Stata 14.2 statistics software package was used
(StataCorp. 2014. Stata Statistical Software: Release 14 Col-
lege Station, Texas: StataCorp LP) and figures were created




Five hundred and fifty-five patients were referred with a
suspected bleeding disorder between January 2012 and
March 2017 and included in the study cohort (►Fig. 1A).
The median age was 43.7 years (IQR 29.3, 61.7) and 371
patients were female (66.9%). Referrals were made by pri-
mary care physicians in 200 cases (36.0%), gynecologists in
121 (21.8%), and other medical specialists in 207 cases
(37.3%). Themost common reason for referral was a bleeding
tendency in 453 cases (81.6%), followed by abnormal coagu-
lation tests in 35 cases (6.3%), a family history in 42 cases
(7.6%), and verification of a known hemostatic disorder (re-
evaluation) in eight cases (1.4%). Antiplatelet drugs were
used by 54 patients (9.7%, stopped 10 days before assess-
ment), 34 patients were being treated with anticoagulant
drugs (6.1%, predominantly vitamin K-antagonists) and 35
patients (6.3%) received selective serotonin reuptake inhib-
itors. The ISTH-BAT was abnormal (male 4 points; female
6 points) in 153 patients referred for a bleeding tendency
(35%), and in 156 patients referred for any reason (28.1%).
Detailed patient characteristics of the study population are
shown in ►Table 1.
Type of Bleeding Disorders
Two hundred and eighty-eight out of 555 patients were
diagnosed with a bleeding disorder (51.9%; ►Table 1); the
type of disorder is reported in ►Fig. 1B. A possible PFD was
identified in 64 patients (11.5%) and a confirmed PFD in 54
cases (9.7%). Von Willebrand disease (or low vonWillebrand
factor) was diagnosed in 50 cases (9.0%), mild hemophilia in
14 cases (2.5%), deficiency of other coagulation factors in
seven cases (1.3%; including six patients with factor XI
deficiency and one patient with factor X deficiency), fibrin-
ogen disorders in six cases (1.1%), disorders of fibrinolysis in
seven cases (1.3%; including one patient with α2-antiplas-
min deficiency, three patients with PAI1 deficiency and three
patients with abnormal clot lysis time), anticoagulant treat-
ment in five cases (0.9%), and a systemic disorder in 38 cases
(6.9%).
Subgroups of PFD
PFDs were categorized into subgroups according to their
laboratory test results (►Table 2). Gi-like defects were diag-
nosed in 38 patients (32.2%), complex disorders in 33 cases
(28.0%), TxA2 pathway defects in 14 (11.9%), diminished
procoagulant COAT platelets in 10 (8.5%), collagen receptor
defects in eigth (6.8%), α-granule disorders in six (5.1%),
dense granule disorders in five (4.2%), and Glanzmann
thrombasthenia in four patients (3.4%). The distribution
according to the diagnostic group (possible vs. confirmed)
is shown in ►Table 2.
PFA Closure Times According to Diagnosis
PFA (ADP, EPI) was conducted in 473 out of 555 patients
(►Table 3). Dataweremissing for one patient with a possible
PFD and in four patients with a confirmed PFD—because PFA
was performed in the referring laboratory.
Median PFA CTs were 101 seconds (ADP; IQR 89, 124) and
157 seconds (EPI; IQR 128, 219) in patients with a possible
PFD. In patients with a confirmed PFD, median CTs were
107 seconds (ADP; IQR 89, 130) and 169 seconds, respective-
ly (EPI; IQR 121, 211). In patients without a bleeding
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Fig. 1 (A) Patient flow. In a prospective cohort study, we collected clinical characteristics and laboratory data from all consecutive patients
referred between January 2012 and March 2017 to an outpatient unit of a university hospital with a suspected bleeding disorder. The diagnostic
work-up was performed following current guidelines and platelet function was tested using light transmission aggregometry as well as flow
cytometry. (B) Classification of patients according to diagnosis. PFD, platelet function disorder; MBD, mild bleeding disorder; VWD, von
Willebrand disease; VWF, von Willebrand factor; FVII, factor VII.
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disorder, PFA CTs were 96 seconds (ADP; IQR 83, 109) and
137 seconds (EPI; IQR 116, 158). Detailed results are reported
in ►Table 3 and ►Fig. 2.
Predictive Value of PFA
The predictive value of the PFA for the presence of (suspected
and confirmed) PFD is illustrated in ►Fig. 3. The area under
the ROC curve was 0.56 (95% CI 0.50, 0.62) in case of ADP and
0.61 in case of EPI (95% CI 0.55, 0.67). Sensitivity and
specificity were calculated according to the in-house refer-
ence ranges (PFA ADP 65–130 seconds; PFA EPI 80–170 sec-
onds). In case of PFA ADP, the sensitivity was calculated to be
19.5% (95% CI 12.6, 30.0) and specificity was 86.4% (95% CI
82.4, 89.8). The positive predictive value was 18.1% (12.4,
25.0), the negative predictive value 77.5% (73.1, 81.5), the
positive likelihood ratio 0.82, and the negative likelihood
ratio 1.1. In case of PFA EPI, sensitivitywas 44.3% (95%CI 34.9,
53.9) and specificity was 75.6% (95% CI 70.8, 79.9), respec-
tively. The positive predictive value was 25.5% (19.9, 31.7),
the negative predictive value was 81.5% (77.0, 85.6), the
positive likelihood ratio was 1.3, and the negative likelihood
ratio 0.84.
We conducted a sensitivity analysis using the reference
ranges of the manufacturer (PFA ADP 62–100 seconds; PFA
EPI 82–150 seconds). In case of ADP, the sensitivitywas 53.1%
(43.5, 62.6) and the specificity was 53.6% (48.3, 58.9). With
regard to EPI, the sensitivity was 61.1% (51.4, 70.1) and the
specificity was 59.2% (53.9, 64.3).
Discussion
We studied a large representative cohort of consecutive
patients with a suspected bleeding disorder. We identified
64 patients with a possible PFD (11.5%) and 54 patients with
a confirmed PFD (9.7%). PFA CTs were only slightly higher in
patients with possible and confirmed PFD and the diagnostic
performance was moderate to poor.
Previous investigations in different settings and using
different study designs revealed inconsistent results. Catta-
neo and colleagues measured PFA CTs in seven patients with










Numbers (%) or median (IQR) as appropriate
Patients 267 (48.0) 64 (11.5) 54 (9.7) 170 (30.6) 0
Age (years) 40.2 (27.3, 60.4) 49.3 (34.9, 63.9) 49.8 (33.5, 64.0) 44.3 (30.7, 61.7) 0
Sex
Female 186 (69.7) 52 (74.3) 32 (66.7) 101 (59.4) 0
Male 81 (30.3) 18 (25.7) 16 (33.3) 69 (40.6) 0
Reason for referral 17
Bleeding tendency 191 (75.5) 63 (98.4) 51 (94.4) 148 (88.6)
Abnormal coagulation
tests
25 (9.9) 1 (1.6) 0 (0) 9 (5.4)
Family history 33 (13.0) 0 (0) 3 (5.6) 6 (3.6)
Re-evaluation 4 (1.6) 0 (0) 0 (0) 4 (2.4)
Referring physician 27
Primary care physician 90 (35.9) 22 (32.8) 20 (42.6) 68 (41.7)
Gynecologist 51 (20.3) 18 (26.9) 18 (38.3) 34 (20.9)
Other specialist 110 (43.8) 27 (40.3) 9 (19.2) 61 (37.4)
ISTH-BAT score 2 (1,3) 4 (2, 7) 7 (5, 9) 4 (2, 7) 15
Antiaggregant treatment 23 (9.5) 11 (17.2) 3 (6.8) 17 (10.8) 47
Anticoagulant treatment 13 (4.9) 3 (4.7) 2 (3.7) 16 (9.5) 3
SSRI treatment 16 (6.7) 8 (14.3) 4 (8.3) 7 (4.1) 57
VWF antigen 110 (82, 136) 101 (79, 136) 98 (79, 133) 93 (57, 134) 72
VWF activity 107 (81, 131) 99 (72, 126) 100 (75, 137) 84 (55, 126) 73
Platelet count 235 (200, 267) 256 (223, 307) 235 (186, 270) 227 (184, 273) 4
Abbreviations: IQR, interquartile range; SSRI, selective serotonin uptake inhibitors; VWF, von Willebrand factor; ISTH-BAT, bleeding assessment tool
of the International Society on Thrombosis and Hemostasis.
aDiagnosis of a platelet function disorder was made using light transmission aggregometry and platelet flow cytometry. “Confirmed platelet
function disorder” was defined as abnormal results in repeated latent transition analysis/flow cytometry measurements in the absence of other
disorders, “possible platelet function disorder” as an abnormal result in one measurement available, inconclusive results, or presence of
concomitant disorder.
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δ-storage pool deficiency, ten patients with primary platelet
secretion defect (PSD), and 40 controls.40 Sensitivity was 41
or 47%, respectively. Harrison et al assessed the potential of
the PFA in a cohort of selected patients.41 Overall sensitivity
was found to be 81% for ADP and 86% for EPI. Buyukasik et al
studied PFA in a cohort of patients with PSDs and controls.42
Sensitivity was 81.6% in this study. Quiroga et al compared
the results of the PFA in patients with mucocutaneous
bleeding to healthy controls.43 The sensitivity was low for
patients with isolated PSD or patients with an unknown
bleeding disorder (24 and 15%, respectively). A low sensitivi-
ty was also observed in a study focusing mainly on preoper-
ative patients.44
There are a number of strengths to our study. We evalu-
ated the PFA in an unselected target population comprising
all patients referred with a suspected bleeding disorder. Any
selection bias is prevented through the consecutive inclusion
of adult Caucasian patients. The number of patients is
considered high and the evaluation was done using a pre-
specified protocol including LTA as well as platelet flow
cytometry. Several potential limitations do appear, however.
First, a number of patients were reluctant to attend the
outpatient unit several times, thus preventing a complete
diagnosticwork-up. To accommodate this, we analyzed these
patients separately (possible PFD) and similar associations
were observed. Second, PFAwas not conduced in a number of
Table 2 Platelet function disorder subgroups (described in Adler et al16)
Disorder Possible PFD (n¼ 64) Confirmed PFD (n¼ 54)
Numbers (%)
Glanzmann’s thrombastheniaa 0 4 (7.4)
Gi-like defectsb 20 (31.3) 18 (33.3)
TxA2 pathway defectsc 13 (20.3) 1 (1.9)
Collagen receptor defectsd 6 (9.4) 2 (3.7)
Dense granule disorderse 1 (1.6) 4 (7.4)
a-granule disordersf 1 (1.6) 5 (9.3)
Diminished procoagulant COAT plateletsg 3 (4.7) 7 (13.0)
Complex disordersh 20 (31.3) 13 (24.1)
Abbreviations: ADP, adenosine diphosphate; PFD, platelet function disorders; TxA2, thromboxane A2. PFD subgroups were defined as follows.
aDefect in GPIIb/IIIa associated with a severely diminished aggregation of all agonists except ristocetin, reduced expression of GPIIb/IIIa, and/or
markedly reduced activation of PAC1-binding.1,3,4,26
bAccentuated deficiency in aggregation to the Gi-coupled receptor antagonists ADP and adrenaline, associated with corresponding flow cytometry
results.1,3,26
cAbsent aggregation in response to arachidonic acid, and possibly associated with an impaired response to other agonists.1,3,4,24,26
dIsolated reduction in aggregation and secretion after stimulation with collagen and convulxin.1,21,26
eDefect in storage and/or secretion of mepacrine.1,3,4,21,26
fReduced expression and/or secretion of P-selectin, associated with varying impaired aggregation after stimulation with collagen and
epinephrine.1,21
gImpaired binding of Annexin-V after incubation with convulxin and thrombin.21
hDefects in a number of agonists (LTA) and/or several flow cytometry results that cannot be attributed to any of the disorders mentioned above.
Table 3 Closure times of PFA according to disease category in a cohort of patients referred with a suspected bleeding disorder
(n¼ 555)
Disorder PFA (ADP) PFA (EPI) Number of patients Missing data
Median closure time in seconds (IQR)
No bleeding disorder 96 (83, 109) 137 (116, 158) 267 48
Possible platelet function disordera 101 (89, 124) 157 (128, 219) 64 1
Confirmed platelet function disordera 107 (89, 130) 169 (121, 211) 54 4
VWD/low VWFb 149 (122, 199) 206 (160, 300) 50 1
Other disorderc 107 (88, 140) 158 (131, 216) 120 28
Abbreviations: EPI, epinephrine; IQR, interquartile range; LTA, light transmission aggregometry; VWD, von Willebrand disease; VWF, vonWillebrand
factor.
aDiagnosis of platelet function disorder was determined using light transmission aggregometry and platelet flow cytometry. “Confirmed platelet
function disorder” was defined as abnormal results in repeated LTA/flow cytometry measurements in the absence of other disorders, “possible
platelet function disorder” as abnormal result in one measurement available, inconclusive results, or presence of concomitant disorders.
bLow von Willebrand values associated with blood group 0; von Willebrand disease type 1 or type 2.
cSystemic disorder associated with bleeding symptoms such as hereditary hemorrhagic telangiectasia and thrombocytopenia.
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patients for a variety of reasons, but we believe this has not
introduced any bias as PFA measurements were nearly
complete in patients with suspected or confirmed PFD. In
addition, tests beyond LTA and flow cytometry were rarely
available in our setting (e.g., molecular diagnostics, ATP
release, fluorescence microscopy). Again, we do not antici-
pate that this introduced any bias. Third, the study popula-
tionwas defined as consecutive patients referred to a tertiary
care center, and one might argue that this does not apply
to secondary care settings where the test is usually applied.
We agree with this argument, but we are nevertheless
convinced that the present study represents the best level
Fig. 2 Closure times of PFA according to the presence of a platelet function disorder. PFA was conducted in a cohort of 555 consecutive patients
referred with a suspected bleeding disorder. Diagnosis of platelet function disorder was achieved using light transmission aggregometry and
platelet flow cytometry.We defined “confirmed platelet function disorder” as abnormal results in repeated LTA/flow cytometry measurements in
the absence of other disorders and “possible platelet function disorder” with an abnormal result in one measurement available, inconclusive
results or presence of concomitant disorders. LTA, light transmission aggregometry. (A) PFA ADP measurements, (B) PFA epinephrine
measurements.
Fig. 3 The receiver operating characteristics (ROC) curve of PFA closure times for the presence of a platelet function disorder. (A) PFA ADP: area
under the ROC curve (AUC): 0.56 (95% CI 0.50, 0.62). At a threshold of 130 seconds, sensitivity was 19.5% (95% CI 12.6, 30.0) and specificity
86.4% (95% CI 82.4, 89.8). (B) PFA EPI: AUC 0.61 (0.55, 0.67). At a threshold of 170 seconds, sensitivity was 44.3% (34.9, 53.9) and specificity was
75.6% (70.8, 79.9). EPI, epinephrine; ADP, adenosine diphosphate; PFD, platelet function disorders.
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of evidence available. As long as no well-designed studies in
primary care are available, we do not see good arguments for
using PFA as a screening tool for PFD in clinical practice.
Fourth, diagnosing PFDs is complex, and no single test covers
all aspects of platelet function.45 Besides, considerable un-
certainty is introduced with every assay because of repro-
ducibility issues and false-positive results. However, we
believe that the combination of LTA and flow cytometry is
a good compromise because it covers many aspects of
platelet function while limiting the number of tests con-
ducted. And, both assays are particularly recommended by
current guidelines.5
Even though PFA is a sensitive assay to detect VWD, it
appears that it is not useful to detect PFD. As long as PFD are
among themost frequent bleeding disorders, few arguments
remain using PFD as a screening tool for bleedingdisorders in
clinical practice. But the question is, what should we do?We
believe that taking the bleeding history using the ISTH BAT is
the most useful test to screen for inherited bleeding disor-
ders. The ISTH BAT is validated in all frequent disorders such
as VWDand PFD.16,22,29However, somemight argue that it is
elaborate and complicated for the inexperienced observer.
Thus, future research shall develop short and concise ver-
sions of the ISTH BAT.
In conclusion, in this large study of consecutive patients
with a suspected bleeding disorder, PFA CTs were only
slightly higher in patients with PFD compared to patients
without a bleeding disorder and the diagnostic performance
was very limited. As long as PFD remains among the most
common hereditary bleeding disorders, our data do not
support the implementation of PFA for the screening of
bleeding disorders in clinical practice.
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